Effects of Amlodipine/Benazepril in the Hypertensive African-American Population With Type 2 Diabetes Mellitus

• Status: Completed
• Trial end date: 2003-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluated the efficacy and safety of amlodipine/benazepril compared with that of enalapril in the treatment of hypertension in African-American patients with type 2 diabetes.

• Phase: Phase 4

Details

• Lead Sponsor: Novartis
• Treatments: Amlodipine; Benazepril

Criteria

Inclusion Criteria:

• African-American

• males and females

• current diagnosis of type 2 diabetes documented by medical history;

• mean sitting diastolic blood pressure of ≥ 90 and ≤ 110 mm Hg;

• HbA1C ≤ 9.5%

Exclusion Criteria:

• having unilateral or bilateral renal artery stenosis;

• having clinically significant cardiac dysrhythmias;

• having a significant history of coronary artery disease within the past 6 months;

• having a history or diagnosis of congestive heart failure (CHF);

• having any clinically relevant cardiac valvular disease